LENZ (LENZ Therapeutics) Total Operating Expense: $138.26 Mil (TTM As of Mar. 2026)


LENZ LENZ Therapeutics Inc LENZ
12 GF Score
Price $5.89
! 2 Warning Signs
View Full Analysis

What is LENZ Therapeutics Total Operating Expense?

LENZ Therapeutics LENZ +1.73% 12 Total Operating Expense is $138.26 Mil as of Mar. 2026. GuruFocus rates LENZ with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

LENZ Therapeutics's Total Operating Expense for the three months ended in Mar. 2026 was $44.96 Mil. LENZ Therapeutics's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $138.26 Mil.

LENZ Therapeutics Total Operating Expense Related Terms

LENZ Therapeutics Total Operating Expense Historical Data

* Premium members only.

The historical data trend for LENZ Therapeutics's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LENZ Therapeutics Total Operating Expense Chart

LENZ Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
6.69 25.48 72.43 58.61 109.81

LENZ Therapeutics Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.93 21.86 31.39 40.05 44.96
LENZ
12GF Score
LENZ Therapeutics Inc LENZ
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LENZ Therapeutics Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $138.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $138.26 Mil mean?
LENZ Therapeutics (LENZ) has a Total Operating Expense of $138.26 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on LENZ Therapeutics and its competitors.
Is LENZ Therapeutics' Total Operating Expense too high?
LENZ Therapeutics' current Total Operating Expense is $138.26 Mil. Overall, LENZ Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does LENZ Therapeutics' Total Operating Expense compare to KRRO and ANTX?
LENZ Therapeutics' Total Operating Expense of $138.26 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on LENZ Therapeutics and its competitors. LENZ Therapeutics's current Total Operating Expense is $138.26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LENZ Therapeutics stock overvalued right now?
LENZ Therapeutics (LENZ) has a current Total Operating Expense of $138.26 Mil. The current Total Operating Expense is $138.26 Mil. LENZ Therapeutics' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For LENZ Therapeutics (LENZ), the current Total Operating Expense is $138.26 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LENZ Therapeutics Business Description

Address 201 Lomas Santa Fe Drive, Suite 300, Solana Beach, CA, USA, 92075
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
12GF Score

Get the complete analysis for LENZ

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.89
Price